1. Scrip
  2. >>Therapy Areas

Eisai gains option to novel cancer therapy, licenses out antifungal

 
• By Ian Haydock

In a flurry of licensing activity, Eisai has acquired an option to a novel targeted cancer therapy from a Japanese bioventure and has awarded the rights to an antifungal prodrug in Japan to a small local firm.

In a flurry of licensing activity, Eisai has acquired an option to a novel targeted cancer therapy from a Japanese bioventure and has awarded the rights to an antifungal prodrug in Japan to a small local firm.

The option deal gives Eisai the right of first review to the results of a US Phase I clinical programme for APS001, a novel oncology project being developed by Anaeropharma Science, a spin-out of Japan's Shinshu University

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapeutic Category

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.